We are live on ! Find out more
PVLA

Palvella Therapeutics
PVLA

93 hedge funds and large institutions have $129M invested in Palvella Therapeutics in 2019 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 24 increasing their positions, 34 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

30% more capital invested

Capital invested by funds: $99M → $129M (+$29.8M)

25% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 12

1% more funds holding

Funds holding: 92 → 93 (+1)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.06% less ownership

Funds ownership: 0.75% → 0.7% (-0.06%)

29% less repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 34

Holders
93
Holders Change
+1
Holders Change %
+1.09%
% of All Funds
2.02%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
15
Increased
24
Reduced
34
Closed
12
Calls
$5K
Puts
–
Net Calls
+$5K
Net Calls Change
+$5K

Top Buyers

1
Millennium Management
Millennium Management
New York
+$2.42M
2
N
Nuveen
North Carolina
+$2.39M
3
ACM
Aquilo Capital Management
California
+$899K
4
OAM
Oxford Asset Management
United Kingdom
+$657K
5
FI
Fosun International
China
+$529K

Top Sellers

1
TCM
Tekla Capital Management
Massachusetts
-$2.38M
2
WCM
Wedge Capital Management
North Carolina
-$1.76M
3
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
-$1.41M
4
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$1.37M
5
Bank of America
Bank of America
North Carolina
-$1.04M
Name Holding Trade Value Shares
Change 		Change in
Stake
RC
51
RBF Capital
California
$263K -$11.9K -40 -5%
Barclays
52
Barclays
United Kingdom
$249K +$141K +474 +252%
Los Angeles Capital Management
53
Los Angeles Capital Management
California
$232K – – –
AGM
54
Alpine Global Management
New York
$212K – – –
Susquehanna International Group
55
Susquehanna International Group
Pennsylvania
$209K +$166K +557 New
Bank of America
56
Bank of America
North Carolina
$206K -$1.04M -3,491 -86%
New York State Common Retirement Fund
57
New York State Common Retirement Fund
New York
$180K – – –
Deutsche Bank
58
Deutsche Bank
Germany
$175K -$148K -495 -51%
AQR Capital Management
59
AQR Capital Management
Connecticut
$167K -$31K -104 -19%
Manulife (Manufacturers Life Insurance)
60
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$152K -$27.1K -91 -18%
AIG
61
American International Group
New York
$138K -$13.7K -46 -11%
Morgan Stanley
62
Morgan Stanley
New York
$117K -$7.46K -25 -7%
VOYA Investment Management
63
VOYA Investment Management
Georgia
$104K – – –
PPA
64
Parametric Portfolio Associates
Washington
$100K +$16.1K +54 +26%
PP
65
Paloma Partners
Connecticut
$92K +$72.8K +244 New
ARTA
66
A.R.T. Advisors
New York
$84K +$66.5K +223 New
CAN
67
Cetera Advisor Networks
California
$72K – – –
Citigroup
68
Citigroup
New York
$61K -$4.18K -14 -8%
UBS Group
69
UBS Group
Switzerland
$60K +$35.8K +120 +300%
Allianz Asset Management
70
Allianz Asset Management
Germany
$54K -$597 -2 -1%
State Board of Administration of Florida Retirement System
71
State Board of Administration of Florida Retirement System
Florida
$51K – – –
Squarepoint
72
Squarepoint
New York
$51K +$40.3K +135 New
Prudential Financial
73
Prudential Financial
New Jersey
$50K +$298 +1 +0.8%
US Bancorp
74
US Bancorp
Minnesota
$48K – – –
CHAM
75
Clear Harbor Asset Management
Connecticut
$47K +$37.3K +125 New
1 2
3
4 5

PVLA Hedge Fund Activity: Q2 2019 in Review

93 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q2 2019, worth a combined $129M — up 30% from $99M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new PVLA positions and 12 closed out — a net gain of 3 holders — while 24 added to existing stakes and 34 trimmed.

The largest buyer was Millennium Management, adding an estimated $2.42M. The largest seller was Tekla Capital Management, cutting an estimated $2.38M.

  • 93 institutional investors held Palvella Therapeutics (PVLA) as of Q2 2019, up from 92 in Q1 2019.
  • Funds reported $129M of Palvella Therapeutics stock for Q2 2019, up 30% quarter-over-quarter.
  • 15 funds opened new Palvella Therapeutics positions in Q2 2019 and 12 closed out, a net change of +3 holders.
  • The largest Palvella Therapeutics buyer in Q2 2019 was Millennium Management, an estimated $2.42M added.
  • The largest Palvella Therapeutics seller in Q2 2019 was Tekla Capital Management, an estimated $2.38M sold.

Based on aggregated 13F filings for Q2 2019.